Experimental Hematology
Volume 35, Issue 4 , Pages 523-533 , April 2007

The pathophysiology of paroxysmal nocturnal hemoglobinuria

  • Charles J. Parker

      Affiliations

    • Corresponding Author InformationOffprint requests to: Charles J. Parker, M.D., Hematology/Oncology Section (111 H), Veterans Affairs Medical Center, 500 Foothill Blvd, Salt Lake City, UT 84114

Received 1 December 2006 ,Revised 18 January 2007 ,Accepted 19 January 2007.

References 

  1. Miyata T, Takeda J, Iida Y, et al. The cloning of PIG-A, a component in the early step of GPI-anchor biosynthesis. Science. 1993;259:1318–1320
  2. Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73:703–711
  3. Miyata T, Yamada N, Iida Y, et al. Abnormalities of PIG-A transcripts in granulocytes from patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1994;330:249–255
  4. Nicholson-Weller A, March JP, Rosenfeld SI, Austen KF. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor. Proc Natl Acad Sci U S A. 1983;80:5066–5070
  5. Pangburn MK, Schreiber RD, Muller-Eberhard HJ. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc Natl Acad Sci U S A. 1983;80:5430–5434
  6. Davitz MA, Low MG, Nussenzweig V. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein. J Exp Med. 1986;163:1150–1161
  7. Holguin MH, Fredrick LR, Bernshaw NJ, Wilcox LA, Parker CJ. Isolation and characterization of a membrane protein from normal human erythrocytes that inhibits reactive lysis of the erythrocytes of paroxysmal nocturnal hemoglobinuria. J Clin Invest. 1989;84:7–17
  8. Holguin MH, Wilcox LA, Bernshaw NJ, Rosse WF, Parker CJ. Erythrocyte membrane inhibitor of reactive lysis: effects of phosphatidylinositol-specific phospholipase C on the isolated and cell-associated protein. Blood. 1990;75:284–289
  9. Parker CJ. Hemolysis in PNH. In:  Young NS,  Moss J editor. Paroxysmal Nocturnal Hemoglobinuria and the Glycosylphosphatidylinositol-Linked Proteins. San Diego: Academic Press; 2000;p. 49
  10. Sloand EM, Young NS. Thrombotic complications in PNH. In:  Young NS,  Moss J editor. Paroxysmal Nocturnal Hemoglobinuria and the Glycosylphosphatidylinositol-Linked Proteins. San Diego: Academic Press; 2000;p. 101–112
  11. Ray JG, Burows RF, Ginsberg JS, Burrows EA. Paroxysmal nocturnal hemoglobinuria and the risk of venous thrombosis: review and recommendations for management of the pregnant and nonpregnant patient. Haemostasis. 2000;30:103–117
  12. Nishimura JI, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;83:193–207
  13. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333:1253–1258
  14. Socie G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. French Society of Haematology. Lancet. 1996;348:573–577
  15. Fujioka S, Takayoshi T. Prognostic features of paroxysmal nocturnal hemoglobinuria in Japan. Acta Haematol Japan. 1989;52:1386–1394
  16. Le XF, Yang TY, Yang XY, Wang XM. Characteristics of paroxysmal nocturnal hemoglobinuria in China. Clinical analysis of 476 cases. Chin Med J (Engl). 1990;103:885–889
  17. Gongora Bianchi RA. Paroxysmal nocturnal hemoglobinuria: the Mexican experience. Rev Invest Clin. 1997;49:85S–88S
  18. Dacie JV, Lewis SM. Paroxysmal nocturnal haemoglobinuria: variation in clinical severity and association with bone-marrow hypoplasia. Br J Haematol. 1961;7:442–457
  19. Dacie JV. Paroxsymal nocturnal haemoglobinuria. Proc R Soc Med. 1963;56:587–596
  20. Lewis SM, Dacie JV. The aplastic anaemia–paroxysmal nocturnal haemoglobinuria syndrome. Br J Haematol. 1967;13:236–251
  21. Parker CJ. Historical aspects of paroxysmal nocturnal haemoglobinuria: “defining the disease.”. Br J Haematol. 2002;117:3–22
  22. Rosse WF, Dacie JV. Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. I. The sensitivity of PNH red cells to lysis by complement and specific antibody. J Clin Invest. 1966;45:736–748
  23. Rosse WF, Dacie JV. Immune lysis of normal human and paroxysmal nocturnal hemoglobinuria (PNH) red blood cells. II. The role of complement components in the increased sensitivity of PNH red cells to immune lysis. J Clin Invest. 1966;45:749–757
  24. Rosse WF. Variations in the red cells in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1973;24:327–342
  25. Holguin MH, Wilcox LA, Bernshaw NJ, Rosse WF, Parker CJ. Relationship between the membrane inhibitor of reactive lysis and the erythrocyte phenotypes of paroxysmal nocturnal hemoglobinuria. J Clin Invest. 1989;84:1387–1394
  26. Oni SB, Osunkoya BO, Luzzatto L. Paroxysmal nocturnal hemoglobinuria: evidence for monoclonal origin of abnormal red cells. Blood. 1970;36:145–152
  27. Endo M, Ware RE, Vreeke TM, et al. Molecular basis of the heterogeneity of expression of glycosyl phosphatidylinositol anchored proteins in paroxysmal nocturnal hemoglobinuria. Blood. 1996;87:2546–2557
  28. Mortazavi Y, Merk B, McIntosh J, Marsh JC, Schrezenmeier H, Rutherford TR. The spectrum of PIG-A gene mutations in aplastic anemia/paroxysmal nocturnal hemoglobinuria (AA/PNH): a high incidence of multiple mutations and evidence of a mutational hot spot. Blood. 2003;101:2833–2841
  29. Bessler M, Mason P, Hillmen P, Luzzatto L. Somatic mutations and cellular selection in paroxysmal nocturnal haemoglobinuria. Lancet. 1994;343:951–953
  30. Nishimura J, Inoue N, Wada H, et al. A patient with paroxysmal nocturnal hemoglobinuria bearing four independent PIG-A mutant clones. Blood. 1997;89:3470–3476
  31. Parker C, Omine M, Richards S, et al. Diagnosis and management of paroxysmal nocturnal hemoglobinuria. Blood. 2005;106:3699–3709
  32. Richards SJ, Cullen MJ, Dickinson AJ, Hall C, Hill A, Hillmen P. Evolution of GPI-deficient clones predicts clinical course in paroxysmal nocturnal hemoglobinuria. Blood. 2004;104:53a
  33. Nishimura Ji J, Hirota T, Kanakura Y, et al. Long-term support of hematopoiesis by a single stem cell clone in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2002;99:2748–2751
  34. Nakao S, Wang H, Chuhjo T. Clinical significance of increased PNH-type cells in the peripheral blood of patients with aplastic anemia and refractory anemia. In:  Omine M,  Kinoshita T editor. Paroxysmal nocturnal hemoglobinuria and related disorders: molecular aspects of pathogenesis. Tokyo: Springer; 2003;p. 129–138
  35. Ishiyama K, Chuhjo T, Wang H, Yachie A, Omine M, Nakao S. Polyclonal hematopoiesis maintained in patients with bone marrow failure harboring a minor population of paroxysmal nocturnal hemoglobinuria–type cells. Blood. 2003;102:1211–1216
  36. Wang H, Chuhjo T, Yamazaki H, et al. Relative increase of granulocytes with a paroxysmal nocturnal haemoglobinuria phenotype in aplastic anaemia patients: the high prevalence at diagnosis. Eur J Haematol. 2001;66:200–205
  37. Wang H, Chuhjo T, Yasue S, Omine M, Nakao S. Clinical significance of a minor population of paroxysmal nocturnal hemoglobinuria–type cells in bone marrow failure syndrome. Blood. 2002;100:3897–3902
  38. Dunn DE, Liu JM, Young NS. Bone marrow failure in PNH. In: Paroxysmal Nocturnal Hemoglobinuria and the Glycosylphosphatidylinositol-Linked Proteins. San Diego: Academic Press; 2000;p. 113
  39. Endo M, Beatty PG, Vreeke TM, Wittwer CT, Singh SP, Parker CJ. Syngeneic bone marrow transplantation without conditioning in a patient with paroxysmal nocturnal hemoglobinuria: in vivo evidence that the mutant stem cells have a survival advantage. Blood. 1996;88:742–750
  40. Rosse WF, Hoffman S, Campbell M, Borowitz M, Moore JO, Parker CJ. The erythrocytes in paroxysmal nocturnal haemoglobinuria of intermediate sensitivity to complement lysis. Br J Haematol. 1991;79:99–107
  41. Young NS, Maciejewski J. The pathophysiology of acquired aplastic anemia. N Engl J Med. 1997;336:1365–1372
  42. Manz CY, Dietrich PY, Schnuriger V, Nissen C, Wodnar-Filipowicz A. T-cell receptor β chain variability in bone marrow and peripheral blood in severe acquired aplastic anemia. Blood Cells Mol Dis. 1997;23:110–122
  43. Risitano AM, Kook H, Zeng W, Chen G, Young NS, Maciejewski JP. Oligoclonal and polyclonal CD4 and CD8 lymphocytes in aplastic anemia and paroxysmal nocturnal hemoglobinuria measured by V β CDR3 spectratyping and flow cytometry. Blood. 2002;100:178–183
  44. Zeng W, Nakao S, Takamatsu H, et al. Characterization of T-cell repertoire of the bone marrow in immune-mediated aplastic anemia: evidence for the involvement of antigen-driven T-cell response in cyclosporine-dependent aplastic anemia. Blood. 1999;93:3008–3016
  45. Kook H, Risitano AM, Zeng W, et al. Changes in T-cell receptor VB repertoire in aplastic anemia: effects of different immunosuppressive regimens. Blood. 2002;99:3668–3675
  46. Karadimitris A, Manavalan JS, Thaler HT, et al. Abnormal T-cell repertoire is consistent with immune process underlying the pathogenesis of paroxysmal nocturnal hemoglobinuria. Blood. 2000;96:2613–2620
  47. Araten DJ, Nafa K, Pakdeesuwan K, Luzzatto L. Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals. Proc Natl Acad Sci U S A. 1999;96:5209–5214
  48. Ware RE, Pickens CV, DeCastro CM, Howard TA. Circulating PIG-A mutant T lymphocytes in healthy adults and patients with bone marrow failure syndromes. Exp Hematol. 2001;29:1403–1409
  49. Hu R, Mukhina GL, Piantadosi S, Barber JP, Jones RJ, Brodsky RA. PIG-A mutations in normal hematopoiesis. Blood. 2005;105:3848–3854
  50. Kawagoe K, Kitamura D, Okabe M, et al. Glycosylphosphatidylinositol-anchor-deficient mice: implications for clonal dominance of mutant cells in paroxysmal nocturnal hemoglobinuria. Blood. 1996;87:3600–3606
  51. Rosti V, Tremml G, Soares V, Pandolfi PP, Luzzatto L, Bessler M. Murine embryonic stem cells without pig-a gene activity are competent for hematopoiesis with the PNH phenotype but not for clonal expansion. J Clin Invest. 1997;100:1028–1036
  52. Murakami Y, Kinoshita T, Maeda Y, Nakano T, Kosaka H, Takeda J. Different roles of glycosylphosphatidylinositol in various hematopoietic cells as revealed by a mouse model of paroxysmal nocturnal hemoglobinuria. Blood. 1999;94:2963–2970
  53. Tremml G, Dominguez C, Rosti V, et al. Increased sensitivity to complement and a decreased red blood cell life span in mice mosaic for a nonfunctional Piga gene. Blood. 1999;94:2945–2954
  54. Wright BE, Longacre A, Reimers JM. Hypermutation in derepressed operons of Escherichia coli K12. Proc Natl Acad Sci U S A. 1999;96:5089–5094
  55. Ball SE, Gibson FM, Rizzo S, Tooze JA, Marsh JC, Gordon-Smith EC. Progressive telomere shortening in aplastic anemia. Blood. 1998;91:3582–3592
  56. Brummendorf TH, Maciejewski JP, Mak J, Young NS, Lansdorp PM. Telomere length in leukocyte subpopulations of patients with aplastic anemia. Blood. 2001;97:895–900
  57. Horikawa K, Kawaguchi T, Ishihara S, et al. Frequent detection of T cells with mutations of the hypoxanthine-guanine phosphoribosyl transferase gene in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2002;99:24–29
  58. Luzzatto L, Nafa K. Genetics of PNH. In:  Young NS,  Moss J editor. Paroxysmal Nocturnal Hemoglobinuria and the Glycosylphosphatidylinositol-Linked Proteins. San Diego: Academic Press; 2000;p. 21–48
  59. Kinoshita T, Inoue N, Takeda J. Defective glycosyl phosphatidylinositol anchor synthesis and paroxysmal nocturnal hemoglobinuria. Adv Immunol. 1995;60:57–103
  60. Ware RE, Howard TA, Kamitani T, Change HM, Yeh ET, Seldin MF. Chromosomal assignment of genes involved in glycosylphosphatidylinositol anchor biosynthesis: implications for the pathogenesis of paroxysmal nocturnal hemoglobinuria. Blood. 1994;83:3753–3757
  61. Rosse WF, Ware RE. The molecular basis of paroxysmal nocturnal hemoglobinuria. Blood. 1995;86:3277–3286
  62. Murakami Y, Kosaka H, Maeda Y, et al. Inefficient response of T lymphocytes to glycosylphosphatidylinositol anchor-negative cells: implications for paroxysmal nocturnal hemoglobinuria. Blood. 2002;100:4116–4122
  63. Hertenstein B, Wagner B, Bunjes D, et al. Emergence of CD52-, phosphatidylinositolglycan-anchor-deficient T lymphocytes after in vivo application of Campath-1H for refractory B-cell non-Hodgkin lymphoma. Blood. 1995;86:1487–1492
  64. Hanaoka N, Kawaguchi T, Horikawa K, et al. Decrease in sensitivity of PIG-A mutant cells to natural killer cells conferred by missing of stress-inducible membrane proteins ULBPs. Blood. 2004;104:774a
  65. Gupta P, Oegema TR, Brazil JJ, Dudek AZ, Slungaard A, Verfaillie CM. Structurally specific heparan sulfates support primitive human hematopoiesis by formation of a multimolecular stem cell niche. Blood. 1998;92:4641–4651
  66. Siebertz B, Stocker G, Drzeniek Z, Handt S, Just U, Haubeck HD. Expression of glypican-4 in haematopoietic-progenitor and bone-marrow-stromal cells. Biochem J. 1999 December 15;344(Pt 3):937–943
  67. Steinfeld R, Van Den Berghe H, David G. Stimulation of fibroblast growth factor receptor-1 occupancy and signaling by cell surface–associated syndecans and glypican. J Cell Biol. 1996;133:405–416
  68. Jackson SM, Nakato H, Sugiura M, et al. Dally, a Drosophila glypican, controls cellular responses to the TGF-β-related morphogen. Dpp. Development. 1997;124:4113–4120
  69. Mast AE, Higuchi DA, Huang ZF, Warshawsky I, Schwartz AL, Broze GJ. Glypican-3 is a binding protein on the HepG2 cell surface for tissue factor pathway inhibitor. Biochem J. 1997;327(Pt 2):577–583
  70. Kim SJ, Letterio J. Transforming growth factor-β signaling in normal and malignant hematopoiesis. Leukemia. 2003;17:1731–1737
  71. Li J, Kleeff J, Kayed H, et al. Glypican-1 antisense transfection modulates TGF-β-dependent signaling in Colo-357 pancreatic cancer cells. Biochem Biophys Res Commun. 2004;320:1148–1155
  72. Paine-Saunders S, Viviano BL, Zupicich J, Skarnes WC, Saunders S. Glypican-3 controls cellular responses to Bmp4 in limb patterning and skeletal development. Dev Biol. 2000;225:179–187
  73. Tam BY, Finnson KW, Philip A. Glycosylphosphatidylinositol-anchored proteins regulate transforming growth factor-β signaling in human keratinocytes. J Biol Chem. 2003;278:49610–49617
  74. Rizzo S, Killick SB, Patel S, et al. Reduced TGF-β1 in patients with aplastic anaemia in vivo and in vitro. Br J Haematol. 1999;107:797–803
  75. Kulkarni S, Bessler M. Effect of proinflammatory cytokines on PIGA-hematopoiesis. Exp Hematol. 2003;31:770–778
  76. Barcellini W, Fermo E, Guia Imperiali F, et al. Increased resistance of PIG-A–bone marrow progenitors to tumor necrosis factor α and interferon γ: possible implications for the in vivo dominance of paroxysmal nocturnal hemoglobinuria clones. Haematologica. 2004;89:651–656
  77. Araten DJ, Swirsky D, Karadimitris A, et al. Cytogenetic and morphological abnormalities in paroxysmal nocturnal haemoglobinuria. Br J Haematol. 2001;115:360–368
  78. Nishimura JI, Inoue N, Azenishi Y, et al. Analysis of PIG-A gene in a patient who developed reciprocal translocation of chromosome 12 and paroxysmal nocturnal hemoglobinuria during follow-up of aplastic anemia. Am J Hematol. 1996;51:229–233
  79. Inoue N, Izui-Sarumaru T, Murakami Y, et al. Molecular basis of clonal expansion of hematopoiesis in two patients with paroxysmal nocturnal hemoglobinuria (PNH). Blood. 2006;108:4232–4236
  80. Meyers G, Babcock WH, Best RG, Parker CJ. Identification of a novel hematopoietic cell translocation in a patient with paroxysmal nocturnal hemoglobinuria. Blood. 2004;104:15b
  81. Borrmann L, Wilkening S, Bullerdiek J. The expression of HMGA genes is regulated by their 3′ UTR. Oncogene. 2001;20:4537–4541
  82. Hess JL, Kossev P. Molecular genetics of benign tumors. Cancer Invest. 2002;20:362–372
  83. Grosschedl R, Giese K, Pagel J. HMG domain proteins: architectural elements in the assembly of nucleoprotein structures. Trends Genet. 1994;10:94–100
  84. Reeves R. Molecular biology of HMGA proteins: hubs of nuclear function. Gene. 2001;277:63–81
  85. Tessari MA, Gostissa M, Altamura S, et al. Transcriptional activation of the cyclin A gene by the architectural transcription factor HMGA2. Mol Cell Biol. 2003;23:9104–9116
  86. Santulli B, Kazmierczak B, Napolitano R, et al. A 12q13 translocation involving the HMGI-C gene in richter transformation of a chronic lymphocytic leukemia. Cancer Genet Cytogenet. 2000;119:70–73
  87. Pierantoni GM, Santulli B, Caliendo I, et al. HMGA2 locus rearrangement in a case of acute lymphoblastic leukemia. Int J Oncol. 2003;23:363–367
  88. Andrieux J, Demory JL, Dupriez B, et al. Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia. Genes Chromosomes Cancer. 2004;39:82–87
  89. Storlazzi CT, Albano F, Locunsolo C, et al. t(3;12)(q26;q14) in polycythemia vera is associated with upregulation of the HMGA2 gene. Leukemia. 2006;20:2190–2192
  90. Odero MD, Grand FH, Iqbal S, et al. Disruption and aberrant expression of HMGA2 as a consequence of diverse chromosomal translocations in myeloid malignancies. Leukemia. 2005;19:245–252
  91. Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2006;355:1233–1243
  92. Luzzatto L, Bessler M, Rotoli B. Somatic mutations in paroxysmal nocturnal hemoglobinuria: a blessing in disguise?. Cell. 1997;88:1–4
  93. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia. Blood. 2003;101:1236–1242

PII: S0301-472X(07)00058-6

doi: 10.1016/j.exphem.2007.01.046

Experimental Hematology
Volume 35, Issue 4 , Pages 523-533 , April 2007

Article Tools

* Image Usage & Resolution